Dynamic interplay between viral adaptation and immune recognition during HIV-1 infection

Protein and Cell

Volumn 1, Issue 6, 2010, Pages 514-519

  Motozono, Chihiro ^a   Mwimanzi, Philip ^a   Ueno, Takamasa ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

cytotoxic T lymphocyte; HIV AIDS; HLA class I; immune escape; peptide MHC complex

Indexed keywords

ARGININE; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHENYLALANINE; T LYMPHOCYTE RECEPTOR; THREONINE; TYROSINE;

ALLELE; AMINO ACID SUBSTITUTION; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS MUTATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650175073     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-010-0068-0     Document Type: Review

References (39)

1. Allen, T. M., Altfeld, M., Geer, S. C., Kalife, E. T., Moore, C., O'sullivan, K. M., Desouza, I., Feeney, M. E., Eldridge, R. L., Maier, E. L., et al. (2005a). Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79, 13239-13249.
2. Allen, T. M., Yu, X. G., Kalife, E. T., Reyor, L. L., Lichterfeld, M., John, M., Cheng, M., Allgaier, R. L., Mui, S., Frahm, N., et al. (2005b). De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 79, 12952-12960.
3. Apostolopoulos, V., Lazoura, E., and Yu, M. (2008). MHC and MHC-like molecules: structural perspectives on the design of molecular vaccines. Adv Exp Med Biol 640, 252-267.
4. Appay, V., Nixon, D. F., Donahoe, S. M., Gillespie, G. M., Dong, T., King, A., Ogg, G. S., Spiegel, H. M., Conlon, C., Spina, C. A., et al. (2000). HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192, 63-75.
5. Baker, B. M., Block, B. L., Rothchild, A. C., and Walker, B. D. (2009). Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 9, 55-69.
6. Bangham, C. R. M. (2009). CTL quality and the control of human retroviral infections. Eur J Immunol 39, 1700-1712.
7. Betts, M. R., Ambrozak, D. R., Douek, D. C., Bonhoeffer, S., Brenchley, J. M., Casazza, J. P., Koup, R. A., and Picker, L. J. (2001). Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75, 11983-11991.
8. Borbulevych, O. Y., Baxter, T. K., Yu, Z., Restifo, N. P., and Baker, B. M. (2005). Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol 174, 4812-4820.
9. Borbulevych, O. Y., Piepenbrink, K. H., Gloor, B. E., Scott, D. R., Sommese, R. F., Cole, D. K., Sewell, A. K., and Baker, B. M. (2009). T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity 31, 885-896.
10. Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., and Oldstone, M. B. (1994). Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68, 6103-6110.
11. Carlson, J. M., and Brumme, Z. L. (2008). HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. Microbes Infect 10, 455-461.
12. Carrington, M., Nelson, G. W., Martin, M. P., Kissner, T., Vlahov, D., Goedert, J. J., Kaslow, R., Buchbinder, S., Hoots, K., and O'Brien, S. J. (1999). HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283, 1748-1752.
13. Feeney, M. E., Tang, Y., Pfafferott, K., Roosevelt, K. A., Draenert, R., Trocha, A., Yu, X. G., Verrill, C., Allen, T., Moore, C., et al. (2005). HIV-1 viral escape in infancy followed by emergence of a variantspecific CTL response. J Immunol 174, 7524-7530.
14. Goulder, P. J. R., Altfeld, M. A., Rosenberg, E. S., Nguyen, T., Tang, Y., Eldridge, R. L., Addo, M. M., He, S., Mukherjee, J. S., Phillips, M. N., et al. (2001). Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193, 181-194.
15. Goulder, P. J. R., and Watkins, D. I. (2004). HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4, 630-640.
16. Hillig, R. C., Hülsmeyer, M., Saenger, W., Welfle, K., Misselwitz, R., Welfle, H., Kozerski, C., Volz, A., Uchanska-Ziegler, B., and Ziegler, A. (2004). Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association. J Biol Chem 279, 652-663.
17. Hülsmeyer, M., Welfle, K., Pöhlmann, T., Misselwitz, R., Alexiev, U., Welfle, H., Saenger, W., Uchanska-Ziegler, B., and Ziegler, A. (2005). Thermodynamic and structural equivalence of two HLA-B27 subtypes complexed with a self-peptide. J Mol Biol 346, 1367-1379.
18. Kosmrlj, A., Read, E. L., Qi, Y., Allen, T. M., Altfeld, M., Deeks, S. G., Pereyra, F., Carrington, M., Walker, B. D., and Chakraborty, A. K. (2010). Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465, 350-354.
19. Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C., and Ho, D. D. (1994). Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68, 4650-4655.
20. Migueles, S. A., Laborico, A. C., Shupert, W. L., Sabbaghian, M. S., Rabin, R., Hallahan, C. W., van Baarle, D., Kostense, S., Miedema, F., McLaughlin, M., et al. (2002). HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3, 1061-1068.
21. Motozono, C., Yanaka, S., Tsumoto, K., Takiguchi, M., and Ueno, T. (2009). Impact of intrinsic cooperative thermodynamics of peptide- MHC complexes on antiviral activity of HIV-specific CTL. J Immunol 182, 5528-5536.
22. Mungall, A. J., Palmer, S. A., Sims, S. K., Edwards, C. A., Ashurst, J. L., Wilming, L., Jones, M. C., Horton, R., Hunt, S. E., Scott, C. E., et al. (2003). The DNA sequence and analysis of human chromosome 6. Nature 425, 805-811.
23. O'Brien, S. J., Gao, X., and Carrington, M. (2001). HLA and AIDS: a cautionary tale. Trends Mol Med 7, 379-381.
24. O'Connell, K. A., Bailey, J. R., and Blankson, J. N. (2009). Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol Sci 30, 631-637.
25. Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M. A., Monard, S., Segal, J. P., Cao, Y., Rowland-Jones, S. L., Cerundolo, V., et al. (1998). Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103-2106.
26. Rammensee, H. G., Friede, T., and Stevanoviíc, S. (1995). MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178-228.
27. Rudolph, M. G., Stanfield, R. L., and Wilson, I. A. (2006). How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24, 419-466.
28. Sáez-Cirión, A., Lacabaratz, C., Lambotte, O., Versmisse, P., Urrutia, A., Boufassa, F., Barré-Sinoussi, F., Delfraissy, J.-F., Sinet, M., Pancino, G., et al., and the Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. (2007). HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104, 6776-6781.
29. Shankarappa, R., Margolick, J. B., Gange, S. J., Rodrigo, A. G., Upchurch, D., Farzadegan, H., Gupta, P., Rinaldo, C. R., Learn, G. H., He, X., et al. (1999). Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73, 10489-10502.
30. Smith, K. J., Reid, S. W., Stuart, D. I., McMichael, A. J., Jones, E. Y., and Bell, J. I. (1996). An altered position of the α2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Immunity 4, 203-213.
31. Stewart-Jones, G. B. E., Gillespie, G., Overton, I. M., Kaul, R., Roche, P., McMichael, A. J., Rowland-Jones, S., and Jones, E. Y. (2005). Structures of three HIV-1 HLA-B*5703-peptide complexes and identification of related HLAs potentially associated with long-term nonprogression. J Immunol 175, 2459-2468.
32. Tomiyama, H., Fujiwara, M., Oka, S., and Takiguchi, M. (2005). Cutting Edge: Epitope-dependent effect of Nef-mediated HLA class I down-regulation on ability of HIV-1-specific CTLs to suppress HIV-1 replication. J Immunol 174, 36-40.
33. Ueno, T., Idegami, Y., Motozono, C., Oka, S., and Takiguchi, M. (2007). Altering effects of antigenic variations in HIV-1 on antiviral effectiveness of HIV-specific CTLs. J Immunol 178, 5513-5523.
34. Ueno, T., Motozono, C., Dohki, S., Mwimanzi, P., Rauch, S., Fackler, O. T., Oka, S., and Takiguchi, M. (2008). CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J Immunol 180, 1107-1116.
35. Ueno, T., Tomiyama, H., Fujiwara, M., Oka, S., and Takiguchi, M. 2004). Functionally impaired HIV-specific CD8 T cells show high affinity TCR-ligand interactions. J Immunol 173, 5451-5457.
36. Yang, O. O., Kalams, S. A., Trocha, A., Cao, H., Luster, A., Johnson, R. P., and Walker, B. D. (1997). Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 71, 3120-3128.
37. Yang, O. O., Sarkis, P. T. N., Trocha, A., Kalams, S. A., Johnson, R. P., and Walker, B. D. (2003). Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol 171, 3718-3724.
38. Yewdell, J. W. (2006). Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25, 533-543.
39. Yu, Z., Theoret, M. R., Touloukian, C. E., Surman, D. R., Garman, S. C., Feigenbaum, L., Baxter, T. K., Baker, B. M., and Restifo, N. P. (2004). Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest 114, 551-559.